Premium valuation, soft growth
The P/E of 47.57× is above the personal care median (35.16×) while profit grew 0.5% last year.
Importance 62 / 95 · valuation
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
The P/E of 47.57× is above the personal care median (35.16×) while profit grew 0.5% last year.
Importance 62 / 95 · valuation
Profit has swung sharply over 4 years (from ₹-561 to ₹1,861) — one year is a weak guide to the earnings power.
Importance 57 / 95 · growth
Free cash flow has been positive in 5 of the last 5 years.
Importance 44 / 95 · cash quality
Classified by the exchange under Fast Moving Consumer Goods › Fast Moving Consumer Goods › Personal Products › Personal Care.
Peer set used on this page: 3 personal care.
Revenue grew 8.0% a year over 4 years, from ₹6,952 cr in FY2022 to ₹9,474 cr in FY2026. Net profit grew 0.6% a year over the same period.
Profit has swung sharply over 4 years (from ₹-561 to ₹1,861) — one year is a weak guide to the earnings power.
Rule EARNINGS_VOLATILE
Revenue has compounded at 5.4% a year over 4 years (₹12,277 → ₹15,178) — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹4,413 cr (up 15.4% on the same quarter last year) and net profit ₹523 cr (up 13.8%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 revenue was ₹4,413 cr, up 15.4% from ₹3,825 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 net profit was ₹523 cr, up 13.8% from ₹459 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 revenue of ₹4,413 cr is the highest of the 14 quarters on record for this company.
Rule QTR_REVENUE_AT_RECORD
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 3,768 | +3.0% | 498 | −14.2% | 13.2% |
| Q4 FY25 | 3,598 | +6.3% | 412 | −121.8% | 11.4% |
| Q1 FY26 | 3,662 | +9.9% | 452 | +0.4% | 12.4% |
| Q2 FY26 | 3,825 | +4.3% | 459 | −6.5% | 12.0% |
| Q3 FY26 | 4,099 | +8.8% | 498 | −0.1% | 12.1% |
| Q4 FY26 | 3,900 | +8.4% | 452 | +9.7% | 11.6% |
| Q1 FY27 | 4,225 | +15.4% | 505 | +11.5% | 11.9% |
| Q2 FY27 | 4,413 | +15.4% | 523 | +13.8% | 11.8% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 25.7% in FY2026, against 25.9% in FY2022. ROE was 18.7% and ROCE 21.1% in FY2026.
Margin and return trends are shown above.
Debt-to-equity was 0.36x in FY2026, against 0.00x in FY2022; interest coverage 11.43x. Operating cash flow was 1.18x net profit.
Free cash flow has been positive in 5 of the last 5 years.
Rule FCF_CONSISTENTLY_POSITIVE
Within its 3-company Personal Care peer group, it ranks 3 of 3 on return on equity and 3 of 3 on EBITDA margin. Its P/E of 47.6 compares with a peer median of 35.2.
Ranked against 3 personal care (FY2026, consolidated).
GODREJCP · 1st of 3 · set median 5.0%
GODREJCP · 3rd of 3 · set median 23.1%
GODREJCP · 3rd of 3 · set median 16.2%
GODREJCP · 3rd of 3 · set median 35.2×
The P/E of 47.57× is above the personal care median (35.16×) while profit grew 0.5% last year.
Rule PRICED_FOR_GROWTH
On the trailing twelve months. Last full year: P/E 50.5× · P/S 6.1× · ROE 15.1%.
The share price is down 18.5% over 1 year, down 8.1% over 3 years (−2.8% a year) and flat over 5 years (flat a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 26.7% below its 52-week high.
Long-term price performance is shown above.
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 6,952 | 7,667 | 8,411 | 8,910 | 9,474 |
| Total income | 7,021 | 7,807 | 8,867 | 9,171 | 9,675 |
| EBITDA | 1,798 | 2,008 | 2,699 | 2,361 | 2,437 |
| Profit before tax | 1,762 | 1,870 | 1,285 | 2,016 | 2,022 |
| Net profit | 1,479 | 1,514 | 647 | 1,351 | 1,516 |
| EPS (₹) | 14.5 | 14.8 | 6.3 | 13.2 | 14.8 |
| Net worth | 7,851 | 9,386 | 9,553 | 8,366 | 7,845 |
| Total debt | 0 | 24 | 1,980 | 2,578 | 2,800 |
| Operating cash flow | 961 | 1,977 | 1,823 | 2,114 | 1,791 |
| Free cash flow | 805 | 1,815 | 1,639 | 1,649 | 1,359 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 10.3 | 9.7 | 5.9 | 6.3 |
| Profit growth YoY | — | 2.3 | -57.3 | 108.7 | 12.2 |
| Profitability | |||||
| EBITDA margin % | 25.9 | 26.2 | 32.1 | 26.5 | 25.7 |
| Net margin % | 21.1 | 19.4 | 7.3 | 14.7 | 15.7 |
| Return on equity % | 18.8 | 17.6 | 6.8 | 15.1 | 18.7 |
| Return on capital % | 21.8 | 22.0 | 24.6 | 19.8 | 21.1 |
| Leverage & cash | |||||
| Debt to equity | 0.00 | 0.00 | 0.21 | 0.31 | 0.36 |
| Cash flow ÷ profit | 0.65 | 1.31 | 2.82 | 1.57 | 1.18 |
| Current ratio | 2.62 | 3.03 | 0.90 | 0.97 | 0.62 |